Insulin-like growth factor-1 (IGF-1) poly (lactic-co-glycolic acid) (PLGA) microparticles–development, characterisation, and in vitro assessment of bioactivity for cardiac applications

Aamir Hameed; Laura B. Gallagher; Eimear Dolan; Janice O’Sullivan; Eduardo Ruiz-Hernandez; Garry P. Duffy; Helena Kelly

doi:10.1080/02652048.2019.1622605

Insulin-like growth factor-1 (IGF-1) poly (lactic-co-glycolic acid) (PLGA) microparticles–development, characterisation, and in vitro assessment of bioactivity for cardiac applications

Aamir Hameed
, Laura B. Gallagher
, Eimear Dolan
, Janice O’Sullivan
, Eduardo Ruiz-Hernandez
, Garry P. Duffy
, Helena Kelly

Royal College of Surgeons in Ireland
Trinity College Dublin
University of Galway

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

13 Citations (Scopus)

Abstract

Aim: The aim of this study was to evaluate the formulation of a synthetic IGF-1 (pIGF-1) in PLGA microparticles (MP). Methods: Poly (lactic-co-glycolic acid) (PLGA) MPs loaded with pIGF-1 were prepared, characterised and evaluated using double emulsion solvent evaporation method. Results: Spherical MPs showed an average particle size of 2 µm, encapsulation efficiency (EE) of 67% and 50% degradation over 15 days. With a view to enhancing retention in the myocardium, the MP formulation was encapsulated in a cross-linked hyaluronic acid hydrogel. pIGF-1 released from MPs and from MPs suspended in hyaluronic acid hydrogel remained bioactive, determined by a significant increase in cellular proliferation of c-kit⁺ cells. Conclusion: This formulation has potential for loco-regional delivery to damaged myocardium to promote the survival of cardiomyocytes.

Original language	English
Pages (from-to)	267-277
Number of pages	11
Journal	Journal of Microencapsulation
Volume	36
Issue number	3
DOIs	https://doi.org/10.1080/02652048.2019.1622605
Publication status	Published - 3 Apr 2019

Keywords

Myocardial infarction
PLGA
bioactivity
cardiac stem cells
human serum albumin
hyaluronic acid
hydrogel
insulin-like growth factor-1
microparticles

Access to Document

10.1080/02652048.2019.1622605

Cite this

Hameed, A., Gallagher, L. B., Dolan, E., O’Sullivan, J., Ruiz-Hernandez, E., Duffy, G. P., & Kelly, H. (2019). Insulin-like growth factor-1 (IGF-1) poly (lactic-co-glycolic acid) (PLGA) microparticles–development, characterisation, and in vitro assessment of bioactivity for cardiac applications. Journal of Microencapsulation, 36(3), 267-277. https://doi.org/10.1080/02652048.2019.1622605

@article{cc47a061d8524ba0958b710bed083c7f,

title = "Insulin-like growth factor-1 (IGF-1) poly (lactic-co-glycolic acid) (PLGA) microparticles{\textendash}development, characterisation, and in vitro assessment of bioactivity for cardiac applications",

abstract = "Aim: The aim of this study was to evaluate the formulation of a synthetic IGF-1 (pIGF-1) in PLGA microparticles (MP). Methods: Poly (lactic-co-glycolic acid) (PLGA) MPs loaded with pIGF-1 were prepared, characterised and evaluated using double emulsion solvent evaporation method. Results: Spherical MPs showed an average particle size of 2 µm, encapsulation efficiency (EE) of 67\% and 50\% degradation over 15 days. With a view to enhancing retention in the myocardium, the MP formulation was encapsulated in a cross-linked hyaluronic acid hydrogel. pIGF-1 released from MPs and from MPs suspended in hyaluronic acid hydrogel remained bioactive, determined by a significant increase in cellular proliferation of c-kit+ cells. Conclusion: This formulation has potential for loco-regional delivery to damaged myocardium to promote the survival of cardiomyocytes.",

keywords = "Myocardial infarction, PLGA, bioactivity, cardiac stem cells, human serum albumin, hyaluronic acid, hydrogel, insulin-like growth factor-1, microparticles",

author = "Aamir Hameed and Gallagher, \{Laura B.\} and Eimear Dolan and Janice O{\textquoteright}Sullivan and Eduardo Ruiz-Hernandez and Duffy, \{Garry P.\} and Helena Kelly",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2019",

month = apr,

day = "3",

doi = "10.1080/02652048.2019.1622605",

language = "English",

volume = "36",

pages = "267--277",

journal = "Journal of Microencapsulation",

issn = "0265-2048",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

Hameed, A, Gallagher, LB, Dolan, E, O’Sullivan, J, Ruiz-Hernandez, E, Duffy, GP & Kelly, H 2019, 'Insulin-like growth factor-1 (IGF-1) poly (lactic-co-glycolic acid) (PLGA) microparticles–development, characterisation, and in vitro assessment of bioactivity for cardiac applications', Journal of Microencapsulation, vol. 36, no. 3, pp. 267-277. https://doi.org/10.1080/02652048.2019.1622605

Insulin-like growth factor-1 (IGF-1) poly (lactic-co-glycolic acid) (PLGA) microparticles–development, characterisation, and in vitro assessment of bioactivity for cardiac applications. / Hameed, Aamir; Gallagher, Laura B.; Dolan, Eimear et al.
In: Journal of Microencapsulation, Vol. 36, No. 3, 03.04.2019, p. 267-277.

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

TY - JOUR

T1 - Insulin-like growth factor-1 (IGF-1) poly (lactic-co-glycolic acid) (PLGA) microparticles–development, characterisation, and in vitro assessment of bioactivity for cardiac applications

AU - Hameed, Aamir

AU - Gallagher, Laura B.

AU - Dolan, Eimear

AU - O’Sullivan, Janice

AU - Ruiz-Hernandez, Eduardo

AU - Duffy, Garry P.

AU - Kelly, Helena

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Aim: The aim of this study was to evaluate the formulation of a synthetic IGF-1 (pIGF-1) in PLGA microparticles (MP). Methods: Poly (lactic-co-glycolic acid) (PLGA) MPs loaded with pIGF-1 were prepared, characterised and evaluated using double emulsion solvent evaporation method. Results: Spherical MPs showed an average particle size of 2 µm, encapsulation efficiency (EE) of 67% and 50% degradation over 15 days. With a view to enhancing retention in the myocardium, the MP formulation was encapsulated in a cross-linked hyaluronic acid hydrogel. pIGF-1 released from MPs and from MPs suspended in hyaluronic acid hydrogel remained bioactive, determined by a significant increase in cellular proliferation of c-kit+ cells. Conclusion: This formulation has potential for loco-regional delivery to damaged myocardium to promote the survival of cardiomyocytes.

AB - Aim: The aim of this study was to evaluate the formulation of a synthetic IGF-1 (pIGF-1) in PLGA microparticles (MP). Methods: Poly (lactic-co-glycolic acid) (PLGA) MPs loaded with pIGF-1 were prepared, characterised and evaluated using double emulsion solvent evaporation method. Results: Spherical MPs showed an average particle size of 2 µm, encapsulation efficiency (EE) of 67% and 50% degradation over 15 days. With a view to enhancing retention in the myocardium, the MP formulation was encapsulated in a cross-linked hyaluronic acid hydrogel. pIGF-1 released from MPs and from MPs suspended in hyaluronic acid hydrogel remained bioactive, determined by a significant increase in cellular proliferation of c-kit+ cells. Conclusion: This formulation has potential for loco-regional delivery to damaged myocardium to promote the survival of cardiomyocytes.

KW - Myocardial infarction

KW - PLGA

KW - bioactivity

KW - cardiac stem cells

KW - human serum albumin

KW - hyaluronic acid

KW - hydrogel

KW - insulin-like growth factor-1

KW - microparticles

UR - https://www.scopus.com/pages/publications/85067576282

U2 - 10.1080/02652048.2019.1622605

DO - 10.1080/02652048.2019.1622605

M3 - Article

SN - 0265-2048

VL - 36

SP - 267

EP - 277

JO - Journal of Microencapsulation

JF - Journal of Microencapsulation

IS - 3

ER -

Insulin-like growth factor-1 (IGF-1) poly (lactic-co-glycolic acid) (PLGA) microparticles–development, characterisation, and in vitro assessment of bioactivity for cardiac applications

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this